<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>478</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15647119</PubmedId>
            <Abstract>BACKGROUND: Synovial sarcoma is a high-grade malignant tumor of soft tissue, characterized by the specific chromosomal translocation t(X;18), and its resultant SYT-SSX fusion gene. Despite intensive multimodality therapy, the majority of metastatic or relapsed diseases still remain incurable, thus suggesting a need for new therapeutic options. We previously demonstrated the antigenicity of SYT-SSX gene-derived peptides by in vitro analyses. The present study was designed to evaluate in vivo immunological property of a SYT-SSX junction peptide in selected patients with synovial sarcoma. METHODS: A 9-mer peptide (SYT-SSX B: GYDQIMPKK) spanning the SYT-SSX fusion region was synthesized. Eligible patients were those (i) who have histologically and genetically confirmed, unresectable synovial sarcoma (SYT-SSX1 or SYT-SSX2 positive), (ii) HLA-A*2402 positive, (iii) between 20 and 70 years old, (iv) ECOG performance status between 0 and 3, and (v) who gave informed consent. Vaccinations with SYT-SSX B peptide (0.1 mg or 1.0 mg) were given subcutaneously six times at 14-day intervals. These patients were evaluated for DTH skin test, adverse events, tumor size, tetramer staining, and peptide-specific CTL induction. RESULTS: A total of 16 vaccinations were carried out in six patients. The results were (i) no serious adverse effects or DTH reactions, (ii) suppression of tumor progression in one patient, (iii) increases in the frequency of peptide-specific CTLs in three patients and a decrease in one patient, and (iv) successful induction of peptide-specific CTLs from four patients. CONCLUSIONS: Our findings indicate the safety of the SYT-SSX junction peptide in the use of vaccination and also give support to the property of the peptide to evoke in vivo immunological responses. Modification of both the peptide itself and the related protocol is required to further improve the therapeutic efficacy.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>1</ArticlePages>
            <ArticleTitle>Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kawaguchi</LastName>
                    <ForeName>Satoshi</ForeName>
                </Author>
                <Author>
                    <LastName>Wada</LastName>
                    <ForeName>Takuro</ForeName>
                </Author>
                <Author>
                    <LastName>Ida</LastName>
                    <ForeName>Kazunori</ForeName>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Yuriko</ForeName>
                </Author>
                <Author>
                    <LastName>Nagoya</LastName>
                    <ForeName>Satoshi</ForeName>
                </Author>
                <Author>
                    <LastName>Tsukahara</LastName>
                    <ForeName>Tomohide</ForeName>
                </Author>
                <Author>
                    <LastName>Kimura</LastName>
                    <ForeName>Sigeharu</ForeName>
                </Author>
                <Author>
                    <LastName>Sahara</LastName>
                    <ForeName>Hiroeki</ForeName>
                </Author>
                <Author>
                    <LastName>Ikeda</LastName>
                    <ForeName>Hideyuki</ForeName>
                </Author>
                <Author>
                    <LastName>Shimozawa</LastName>
                    <ForeName>Kumiko</ForeName>
                </Author>
                <Author>
                    <LastName>Asanuma</LastName>
                    <ForeName>Hiroko</ForeName>
                </Author>
                <Author>
                    <LastName>Torigoe</LastName>
                    <ForeName>Toshihiko</ForeName>
                </Author>
                <Author>
                    <LastName>Hiraga</LastName>
                    <ForeName>Hiroaki</ForeName>
                </Author>
                <Author>
                    <LastName>Ishii</LastName>
                    <ForeName>Takeshi</ForeName>
                </Author>
                <Author>
                    <LastName>Tatezaki</LastName>
                    <ForeName>Shin-Ichiro</ForeName>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Noriyuki</ForeName>
                </Author>
                <Author>
                    <LastName>Yamashita</LastName>
                    <ForeName>Toshihiko</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan. kawaguch@sapmed.ac.jp.</Affiliations>
            <Journal>
                <Volume>3</Volume>
                <Issue>1</Issue>
                <Title>Journal of translational medicine</Title>
                <Issn>1479-5876</Issn>
                <MedlineTa>J Transl Med</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>SYT-SSX B</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GYDQIMPKK</LinearSequence>
                        <StartingPosition>17</StartingPosition>
                        <EndingPosition>25</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>CAB36970.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>23322</EpitopeId>
                <ReferenceStartingPosition>17</ReferenceStartingPosition>
                <ReferenceEndingPosition>25</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>3183</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>M</Sex>
                                <Age>21</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:305</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GYDQIMPKK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SYT-SSX B</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GYDQIMPKK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>6 vaccinations (1.0 mg freeze-dried peptide powder dissolved in 1.0 ml physiological saline) with SYT-SSX B peptide were given at 14-day intervals to this patient.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>SYT-SSX B peptide</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GYDQIMPKK</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB36970.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Effector to target cell ratios (E/T) = 3, 10 or 30. The percent of specific lysis of target cells was always above control with any of the E/T ratios used. Negative controls were no peptide and HIV peptide-pulsed T2 cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>7818</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>M</Sex>
                                <Age>21</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:305</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GYDQIMPKK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SYT-SSX B</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GYDQIMPKK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>6 vaccinations (1.0 mg freeze-dried peptide powder dissolved in 1.0 ml physiological saline) with SYT-SSX B peptide were given at 14-day intervals to this patient.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>SYT-SXX protein</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>CAB36970.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>1</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>1</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Effector to target cell ratios (E/T) = 3, 10 or 30. The percent of specific lysis of target cells was always above control in any of the E/T ratios used. Cytotoxicity was also observed with the synovial sarcoma cell line HS-SY-II. Negative controls were SW982 and K562 (cell lines lacking HLA-A24).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2 and figure 3</LocationOfData>
                        <TCellId>3203</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:305</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SYT-SXX protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GYDQIMPKK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>CAB36970.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Up to 6 SYT-SSX B peptide vaccinations were given at 14-day interval to synovial sarcoma patients; PBMCs were isolated afterwards  to determine SYT-SSX B peptide-specific CD8+ cells.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>SYT-SSX B</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GYDQIMPKK</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>CAB36970.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Peptide-specific CD8+ cells were already present (values above control in tetramer analysis) for 2 patients pre-vaccination. After the 1st vaccination 4/5 patients had values above control values; after 3rd vaccination 3/5 had values above control values and 2/3 did after the 6th vaccination. Essentially all patients were positive for peptide-specific CD8+ cells pre or post-vaccination.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

